Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

October 12, 2017: By Jon Swedien

NicoxNicox and pSivida have agreed to potentially combine Nicox’s nitric oxide (NO)-donating compounds with pSivida’s bioerodible sustained-release drug delivery system to develop an IOP-lowering treatment for glaucoma and ocular hypertension, the companies announced Oct. 10.

Nicox and pSivida will collaborate on the selection of NO-donating product candidates from Nicox’s research portfolio to combine with pSivida’s technology. pSivida will be responsible for initial development activities and receive undisclosed payments from Nicox, the companies said.

pSividaThe firms may elect to conduct more detailed nonclinical studies to generate preclinical data and evaluate additional compounds. Nicox would make additional payments for any incremental development activities for each product candidate selected by Nicox to advance, the companies said.

New intellectual property from the collaboration will be jointly owned, the companies said. Nicox and pSivida will negotiate a separate license agreement for any product candidate they plan to commercialize under the collaboration, they said.

Expected payments from Nicox associated with this agreement are not considered material to Nicox’s financial statements at this time, the company said.

Nicox is an international ophthalmic company based in Paris. pSivida, headquartered in Watertown, Massachusetts, is focused on sustained-release drug products for treating eye diseases.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility